View ValuationPRF Technologies 将来の成長Future 基準チェック /06現在、 PRF Technologiesの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長14.0%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報Price target decreased to US$3.00 Nov 16Price target decreased to US$3.00 Apr 27Forecast to breakeven in 2025 May 22すべての更新を表示Recent updatesPRF Technologies Ltd. Announces FDA Clearance Of IND Application For OcuRing-K Phase II Clinical TrialApr 30Less than half of directors are independent Mar 12PRF Technologies Ltd. Files Its First Patent Application for Solar Plant Micro-Climate Forecast Modeling Designed to Improve Energy Production Forecast AccuracyJan 21New major risk - Share price stability Jan 20PainReform Ltd. and LayerBio, Inc. Announces Safety Data Supporting the Continued Development of OcuRing-K Drop-less, Sustainable-Release Ocular Drug Delivery Platform for Use in Cataract SurgeryJan 13PainReform Ltd.'s Deepsolar Launches Smart TDD, A Next-Generation Solar Due Diligence Service Targeting the $60B+ Global Solar Asset M&A MarketJan 06Painreform Ltd. Announces Its Pharmaceutical Division Has Completed an R&D Assessment of Layerbio's Proprietary Drop-Less, Sustained-Release Ocular Drug-Delivery PlatformDec 11PainReform Ltd. Commences Development for OcuRing™?-K Phase II Trial, LayerBio's Drop-Less Sustained-Release Ocular TherapyDec 03PainReform Ltd., Annual General Meeting, Dec 30, 2025Nov 26PainReform's DeepSolar Advances Development of its AI-Driven Automated Reporting Engine for Solar-Asset AnalysisNov 13New major risk - Share price stability Aug 19New major risk - Revenue and earnings growth Apr 16PainReform Ltd. (NasdaqCM:PRFX) completed the acquisition of Business Activities Associated with the DeepSolar Technology of BladeRanger Ltd.Mar 07New minor risk - Financial data availability Mar 03PainReform Ltd. (NasdaqCM:PRFX) entered into a business acquisition agreement to acquire Business Activities Associated with the DeepSolar Technology of BladeRanger Ltd for ILS 1.8 million.Feb 19PainReform Ltd. Provides Further Update on Phase 3 Clinical Trial of PRF-110Dec 27Painreform Ltd. Announces CFO ChangesDec 06PainReform Ltd. Announces Initial Topline Data for PRF-110 Phase 3 Clinical TrialNov 20PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity RequirementNov 08PainReform Ltd. has filed a Follow-on Equity Offering in the amount of $1.35 million.Oct 17PainReform Ltd., Annual General Meeting, Sep 30, 2024Aug 29PainReform Ltd. Announces Successful Determination of Optimal Delivery Method for PRF-110 in Bunionectomy ProceduresAug 22painReform Ltd. Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy StudyAug 20New major risk - Financial position Aug 18PainReform Ltd. Announces Development and Successful Manufacturing of New Formulations Providing Anti-Inflammatory and Extended Analgesic EffectsAug 13PainReform Ltd. Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher DosesAug 08PainReform Ltd. Announces Favorable Wound Healing Data in Human Clinical Trials for PRF-110Aug 06PainReform Ltd. Announces New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room TemperatureAug 02PainReform Ltd. Files Patent Covering Highly Scalable Manufacturing Process for PRF-110 Following Successful Completion and TestingJul 25PainReform Ltd. Completes Enrollment in the Second Part of Its Phase 3 Bunionectomy Trial for Prf-110Jun 26New major risk - Share price stability Jun 14PainReform Ltd. has completed a Follow-on Equity Offering in the amount of $7.999045 million.Apr 19Painreform Ltd. Announces Groundbreaking Results from New Studies Demonstrating the Superior In-Vitro Release Rates of PRF-110Apr 12PainReform Ltd. Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in BunionectomyApr 02PainReform Ltd. has filed a Follow-on Equity Offering in the amount of $5 million.Mar 02New major risk - Shareholder dilution Jan 21Insufficient new directors Oct 01PainReform Ltd. Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master FileSep 13PainReform Ltd. Announces Selection for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, HungarySep 08We're Keeping An Eye On PainReform's (NASDAQ:PRFX) Cash Burn RateJul 03New major risk - Revenue and earnings growth Jun 11PainReform Ltd. Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy SurgeryJun 08New major risk - Financial position Jun 08PainReform Ltd. Announces Positive Pharmacokinetic (PK) Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy SurgeryMay 19PainReform Ltd., Annual General Meeting, Jun 08, 2023May 05PainReform Announces Receipt of Extension to Meet the Nasdaq’s Minimum Bid Price RequirementFeb 09PainReform Ltd., Annual General Meeting, Dec 29, 2022Nov 26Price target decreased to US$3.00 Nov 16PainReform Ltd. Provides Further Update on Manufacturing of PRF-110Nov 09PainReform Ltd. Provides PRF-110 Manufacturing UpdateOct 06PainReform Announces Receipt of Nasdaq Minimum Bid Price NotificationAug 17PainReform reports results Aug 16Price target decreased to US$3.00 Apr 27We're Hopeful That PainReform (NASDAQ:PRFX) Will Use Its Cash WiselySep 19Companies Like PainReform (NASDAQ:PRFX) Are In A Position To Invest In GrowthMay 23Forecast to breakeven in 2025 May 22PainReform Ltd. announced that it has received $5.999992 million in fundingMar 21Director has left the company Mar 10PainReform Ltd. announced that it expects to receive $5.999992 million in fundingMar 09PainReform Ltd. Announces Resignation of Assif Stoffman from Board of DirectorsMar 04New 90-day high: US$5.66 Feb 10PainReform Ltd. Appoints Rita Keynan as Vice President of Pharmaceutical OperationsJan 08New 90-day low: US$4.06 Jan 07PainReform Appoints Ilan Hadar as Chief Executive OfficerNov 24PainReform Ltd. Welcomes Ellen Baron as A Member of Board of DirectorsNov 14PainReform Ltd. Appoints Augustine Lawlor as Member of Board of DirectorsNov 10PainReform Ltd. has completed an IPO in the amount of $20 million.Sep 02 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、PRF Technologies は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測NasdaqCM:PRFX - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20250-5-4-4N/A9/30/20250-4-5-5N/A6/30/2025N/A-4-6-6N/A3/31/2025N/A-10-10-10N/A12/31/2024N/A-15-13-13N/A9/30/2024N/A-19-12-12N/A6/30/2024N/A-18-11-11N/A3/31/2024N/A-13-8-8N/A12/31/2023N/A-9-7-7N/A9/30/2023N/A-8-8-8N/A6/30/2023N/A-10-8-8N/A3/31/2023N/A-9-7-7N/A12/31/2022N/A-9-6-6N/A9/30/2022N/A-7-5-5N/A6/30/2022N/A-7-6-6N/A3/31/2022N/A-7-6-6N/A12/31/2021N/A-7-7-7N/A9/30/2021N/A-7-7-7N/A6/30/2021N/A-5-6-6N/A3/31/2021N/A-5-4-4N/A12/31/2020N/A-4-3-3N/A9/30/2020N/A-4-1-1N/A6/30/2020N/A-4-1-1N/A3/31/2020N/A-4-1-1N/A12/31/2019N/A-2-1-1N/A9/30/2019N/A-2N/A-1N/A6/30/2019N/A-2N/A0N/A3/31/2019N/A-2N/A-1N/A12/31/2018N/A-2N/A-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: PRFXの予測収益成長が 貯蓄率 ( 3.4% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: PRFXの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: PRFXの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: PRFXの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: PRFXの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: PRFXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日(UTC時間)企業分析2026/05/03 16:37終値2026/05/01 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PRF Technologies Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Jason McCarthyMaxim GroupNazibur RahmanMaxim Group
PRF Technologies Ltd. Announces FDA Clearance Of IND Application For OcuRing-K Phase II Clinical TrialApr 30
PRF Technologies Ltd. Files Its First Patent Application for Solar Plant Micro-Climate Forecast Modeling Designed to Improve Energy Production Forecast AccuracyJan 21
PainReform Ltd. and LayerBio, Inc. Announces Safety Data Supporting the Continued Development of OcuRing-K Drop-less, Sustainable-Release Ocular Drug Delivery Platform for Use in Cataract SurgeryJan 13
PainReform Ltd.'s Deepsolar Launches Smart TDD, A Next-Generation Solar Due Diligence Service Targeting the $60B+ Global Solar Asset M&A MarketJan 06
Painreform Ltd. Announces Its Pharmaceutical Division Has Completed an R&D Assessment of Layerbio's Proprietary Drop-Less, Sustained-Release Ocular Drug-Delivery PlatformDec 11
PainReform Ltd. Commences Development for OcuRing™?-K Phase II Trial, LayerBio's Drop-Less Sustained-Release Ocular TherapyDec 03
PainReform's DeepSolar Advances Development of its AI-Driven Automated Reporting Engine for Solar-Asset AnalysisNov 13
PainReform Ltd. (NasdaqCM:PRFX) completed the acquisition of Business Activities Associated with the DeepSolar Technology of BladeRanger Ltd.Mar 07
PainReform Ltd. (NasdaqCM:PRFX) entered into a business acquisition agreement to acquire Business Activities Associated with the DeepSolar Technology of BladeRanger Ltd for ILS 1.8 million.Feb 19
PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity RequirementNov 08
PainReform Ltd. Announces Successful Determination of Optimal Delivery Method for PRF-110 in Bunionectomy ProceduresAug 22
PainReform Ltd. Announces Development and Successful Manufacturing of New Formulations Providing Anti-Inflammatory and Extended Analgesic EffectsAug 13
PainReform Ltd. Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher DosesAug 08
PainReform Ltd. Announces New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room TemperatureAug 02
PainReform Ltd. Files Patent Covering Highly Scalable Manufacturing Process for PRF-110 Following Successful Completion and TestingJul 25
PainReform Ltd. Completes Enrollment in the Second Part of Its Phase 3 Bunionectomy Trial for Prf-110Jun 26
Painreform Ltd. Announces Groundbreaking Results from New Studies Demonstrating the Superior In-Vitro Release Rates of PRF-110Apr 12
PainReform Ltd. Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in BunionectomyApr 02
PainReform Ltd. Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master FileSep 13
PainReform Ltd. Announces Selection for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, HungarySep 08
PainReform Ltd. Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy SurgeryJun 08
PainReform Ltd. Announces Positive Pharmacokinetic (PK) Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy SurgeryMay 19